Evidence map›Paper›PMID 39653871›Full record

ArticleInternational journal of hematology2025

Temporal changes in corticosteroid dose during ibrutinib treatment in patients with cGVHD and pulmonary involvement.

Masako Toyosaki, Shinichiro Machida, Daisuke Tomizawa, Masaya Okada, Masashi Sawa, Yasunori Ueda, Ai Omi, Yosuke Koroki, Takanori Teshima

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masako ToyosakiDepartment of Hematology and Oncology, Tokai University Hospital, Isehara, Japan.
Shinichiro MachidaDepartment of Hematology and Oncology, Tokai University Hospital, Isehara, Japan.
Daisuke TomizawaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Masaya OkadaDivision of Hematology and Oncology, Kansai Medical University General Center, Osaka, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Yasunori UedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Ai OmiMedical Affairs Division, Janssen Pharmaceutical K.K, 3-5-2 Nishi-kanda, Chiyoda-ku, Tokyo, 101-0065, Japan. AOmi@ITS.JNJ.com.ORCID http://orcid.org/0000-0001-9391-5661
Yosuke KorokiMedical Affairs Division, Janssen Pharmaceutical K.K, 3-5-2 Nishi-kanda, Chiyoda-ku, Tokyo, 101-0065, Japan.
Takanori TeshimaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The GVH3001 study assessed the efficacy and safety of ibrutinib in Japanese patients with steroid-dependent or -refractory chronic graft-versus-host disease (cGVHD). However, the effects of ibrutinib on lung function and reduction in corticosteroid dose, which is a measurable factor associated with improved quality of life, could not be adequately assessed in patients who initially presented with lung involvement. This post hoc analysis aimed to evaluate temporal changes in daily corticosteroid dose, as well as effectiveness outcomes based on lung function and symptom burden (percent predicted forced expiratory volume in 1 s [%FEV

Indexed as

Adrenal Cortex HormonesGraft vs Host DiseaseLung DiseasesPyrazolesPyrimidinesAdenineAdultAgedChronic DiseaseFemaleHumansMaleMiddle AgedPiperidinesTreatment OutcomeAdenineAdrenal Cortex HormonesibrutinibPiperidinesPyrazolesPyrimidinesChronic graft-versus-host diseaseCorticosteroidsIbrutinibJapanLung

Identifiers

PMID39653871
PMCPMC11861523

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.